mortality/aging
• in mice treated with MOG 35-55
|
immune system
• increased
|
• in T cells from MOG 35-55-treated mice re-stimulated with anti-CD3/CD28 T cells
|
• during Th17 differentiation
|
• decreased IL17a secretion from splenocytes from MOG 35-55-treated mice
|
• during Th17 differentiation
|
• mice treated with MOG 35-55 exhibit increased mortality and increased maximum clinical score compared with control mice
|
homeostasis/metabolism
• in T-cells stimulated with anti-CD3/CD28 and IL2 compared with similarly treated T cells from Smad7tm1.1Ink/Smad7tm1.1Ink Tg(Cd4-cre)1Cwi mice
|
hematopoietic system
• increased
|